January

January 22, 2018

Natural product-derived therapy for attenuating pathogenesis-associated with Myocardial infarction: A pharmaceutical mixture encompassing Naringenin, Genesenoside and Fortunellin (NGF) decreases IRF3, GM-CSF (Granulocyte-macrophage colony-stimulating factor) and GRK2(G protein-coupled receptor kinase) expression, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits ventricular dilation, and promotes heart repair and survival via up regulation of its target gene, 23/January/2018, 5.18 am

Introduction: What they say: A recent study from Department of Systems Biology, Harvard Medical School, Boston, Massachusetts, USA; and Cardiovascular Research Center, Massachusetts General Hospital and […]
January 22, 2018

Molecular therapy for Metastatic cancers: Metformin, an anti-hyperglycemic drug, increases the expression of tumor/metastatic suppressors BTG2 and INK4a , inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 23/January/2018, 5.16 am

From significance of the study to Public health relevance:  Given that: (i) each year nearly 14 million people are diagnosed with cancer globally, and little more […]
January 21, 2018

Combinatorial therapy for Deafness: A therapeutic mix encompassing Sildenafil, Cholecalciferol, Ajoene and DIM (SFCAD) increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration,  improves hearing loss via up regulation of its target genes, 21/January/2018, 11.11 pm

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Combinatorial therapy for Deafness: A therapeutic mix encompassing Sildenafil, Cholecalciferol, Ajoene and DIM (SFCAD) increases the […]
January 21, 2018

Molecular therapy for Diabetic nephropathy (DN): Atrasentan, a drug used in the treatment of diabetic kidney disease and cancer, increases Pyruvate kinase M2 (PKM2) expression, decreases toxic glucose metabolites, mitochondrial dysfunction and apoptosis, augments glycolytic flux and PGC-1α levels, improves metabolic abnormalities, albuminuria, glomerular pathology, and renal dysfunction and alleviates diabetic nephropathy via down regulation of its target gene, 21/January/2018, 11.02 pm

Introduction: What they say A study from the Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts, USA shows that “Pyruvate kinase M2 activation may protect against the […]